AI Article Synopsis
- Venom-specific immunotherapy (VIT) is crucial for treating patients allergic to insect venom, focusing on accurate diagnosis and treatment selection.
- A 9-year retrospective study in Lithuania analyzed 83 patients, revealing a 39.4% rate of double sensitization and a 7.4% incidence of systemic reactions during treatment.
- The study concluded that the VIT protocol was safe and effective, though patient motivation to continue treatment and challenges with bee venom allergies posed significant concerns.
Article Abstract
Background: Venom-specific immunotherapy (VIT) is a major treatment for patients allergic to venom. Thus, correct diagnosis of sensitization, identification of the risk factors, and choice of venom for the treatment are the key issues.
Objective: We aimed to describe diagnostic and treatment experience data of VIT performed in a single center in Lithuania.
Methods: In this retrospective study, we analyzed 9 years of clinical data (severity of the allergic reaction, recognition of the culprit insects, diagnostics, VIT protocol safety and efficacy, sting challenge outcomes) of patients treated with cluster VIT. Sting challenge helped to reveal the influence of venom preparation quality and to adjust the dosage of venom.
Results: Data from 83 patients were analyzed. Double sensitization confirmed by component diagnosis was found in 39.4% (13/33), and double immunotherapy was initiated in 9.1% (n = 3/33). The cluster immunotherapy protocol was used in 81 patients. Systemic reactions occurred in 7.4% (n = 6/81) patients during the build-up phase. VIT failure was related to bee venom immunotherapy and systemic reactions during a build-up phase. The efficacy in the short term of our approach to cluster VIT was confirmed by the sting challenge in 97% (42/43). Nine patients (10.8%, n = 9/83) voluntarily stopped the treatment due to a lack of motivation.
Conclusion: Our protocol regarding the investigation and treatment of patients allergic to venom has been safe and effective. Patient's motivation to continue VIT is one of the concerns, but the biggest challenge is the patients with bee venom allergy and repeated systemic reactions during VIT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10937955 | PMC |
| http://dx.doi.org/10.1016/j.waojou.2024.100884 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antigens and adjuvants co-stabilized Pickering emulsions amplify immune responses of subunit vaccines.
J Control Release
January 2025
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China. Electronic address:
Most subunit antigens often induce suboptimal vaccination efficacy, possibly due to their low immunogenicity and limited ability to migrate to lymph nodes (LNs). Although the emergence of nanovaccine has significantly addressed these challenges, most formulations still require specific biological or chemical modifications to the carrier or antigen for efficient antigen loading. In this study, we report a Pickering emulsion-based nanovaccine that directly utilized antigens and adjuvants as stabilizers, effectively amplifying immune responses without additional physicochemical alterations.
View Article and Find Full Text PDFPlatinum(IV)-Backboned Polymer Prodrug-Functionalized Manganese Oxide Nanoparticles for Enhanced Lung Cancer Chemoimmunotherapy via Amplifying Stimulator of Interferon Genes Activation.
ACS Nano
January 2025
Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, P. R. China.
The stimulator of interferon genes (STING) pathway exhibits great potential in remodeling the immunosuppressive tumor microenvironment and initiating antitumor immunity. However, how to effectively activate STING and avoid undesired toxicity after systemic administration remains challenging. Herein, platinum(IV)-backboned polymer prodrug-coated manganese oxide nanoparticles (DHP/MnONP) with pH/redox dual responsive properties are developed to precisely release cisplatin and Mn in the tumor microenvironment and synergistically amplify STING activation.
View Article and Find Full Text PDFCellular and Humoral Response After Induction of Protection and After Finishing Venom Immunotherapy.
Biomolecules
November 2024
Laboratory for Clinical Immunology and Molecular Genetics, University Clinic of Respiratory and Allergic Diseases Golnik, 4204 Golnik, Slovenia.
venom allergy (HVA) is an IgE-mediated hypersensitivity reaction caused by species stings (honeybee, vespid, or ant). The only effective treatment is venom immunotherapy (VIT). Our study aimed to evaluate whether humoral and cellular biomarkers measured before, during, and after honeybee VIT are associated with the success of VIT, which was assessed by the response to a sting challenge one year after finishing VIT.
View Article and Find Full Text PDFExploring Beekeepers' Experiences and Perceptions of Anaphylaxis Risks: A Qualitative Study to Inform Targeted Health Education Programs.
Healthcare (Basel)
December 2024
Faculty of Health Sciences, University of Primorska, 6310 Izola, Slovenia.
Background: Beekeeping plays crucial natural and economic roles but also poses health risks, as bee stings can cause severe allergic reactions like anaphylaxis, a potentially life-threatening condition that requires timely intervention. Understanding symptoms and the proper use of adrenaline autoinjectors is essential to minimize risks. This study aimed to assess the need for education on anaphylaxis and to develop a health education program to enhance beekeepers' preparedness and safety.
View Article and Find Full Text PDFA SARS-CoV-2 mucosal nanovaccine based on assembly of maltodextrin, STING agonist and polyethyleneimine.
Int J Biol Macromol
January 2025
State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China. Electronic address:
SARS-CoV-2 has the characteristics of strong transmission with severe morbidity and mortality. Protein-based vaccines have the properties of specificity, effectiveness and safety against SARS-CoV-2. Receptor-binding domain (RBD) homotrimer affords high protection efficacy against stringent lethal viral challenge.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!